Stock PHVS PHARVARIS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Real-time Estimate Cboe BZX
Other stock markets
 03:55:32 2024-07-09 pm EDT 		5-day change 1st Jan Change
17.3 USD -0.75% Intraday chart for Pharvaris N.V. +2.40% -38.48%
Jul. 03 Oppenheimer Raises Price Target on Pharvaris to $38 From $36, Maintains Outperform Rating MT
Jun. 04 Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Pharvaris N : .V Form 6 K
PU
Pharvaris N : Annual Report 2023
PU
Pharvaris Announces Annual Meeting of Shareholders
GL
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
GL
Pharvaris N : Development of Kallikrein Kinin System Biomarker Assays to Investigate Bradykinin mediated Diseases
PU
Pharvaris N : Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema
PU
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
GL
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
GL
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
GL
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
GL
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
AQ
Pharvaris N : Poster
PU
Pharvaris N : EGM Meeting Minutes
PU
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K
PU
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
GL
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
AQ
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
GL
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHVS Stock
  4. News Pharvaris N.V.
  5. Press Releases